Flisiak, Robert <br/><br/>
Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.  [electronic resource] 

 -  Expert review of gastroenterology & hepatology  Jun 2017 
 - 559-567 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1747-4132 
<br/><br/><label>Standard No.: </label>10.1080/17474124.2017.1309284  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Administration, Oral<br/>Anilides--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Cyclopropanes<br/>Drug Combinations<br/>Drug Interactions<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--diagnosis<br/>Humans<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--administration & dosage<br/>Proline--analogs & derivatives<br/>Ritonavir--administration & dosage<br/>Sulfonamides--adverse effects<br/>Sustained Virologic Response<br/>Treatment Outcome<br/>Uracil--adverse effects<br/>Valine